title: [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
abstract: OBJECTIVE
  Distant metastasis was common in lung cancer, especially patients with bone marrow metastasis had poor prognosis and there were few effective methods. Crizotinib had been confirmed to be used in anaplastic lymphoma kinase (ALK) positive lung adenocarcinoma, but the efficacy in lung cancer with bone marrow metastasis was unknown. In the present study, we reported one case of ALK-positive lung adenocarcinoma with bone marrow matastasis given crizotinib treatment, the safety and efficacy was summarized.
  
  
  METHODS
  ALK fusion was tested by fluorescence in situ hybridization (FISH). Crizotinib was given with dose of 250 mg, bid. Objective response was evaluated by Response Evaluation Criteriation in Solid Tumours (RECIST) v1.1 and bone marrow response was evaluated by bone marrow puncture and biopsy. Adeverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTC AE) v4.0.
  
  
  RESULTS
  The patient achieved partial response (PR) after 6 weeks of crizotinib, especially the objective response of bone marrow metastasis was complete response (CR). The patient stopped crizotinib because of pneumonia. The progression free survival (PFS) and overall survival (OS) was 20 weeks and 22 weeks respectively.
  
  
  CONCLUSIONS
  Crizotinib could be an effective method for ALKpositive lung cancer with bone marrow metastasis and showed good tolerance.
authors: Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military Medical Sciences, Beijing 100071, China.
authors: Xiaoyan
authors: X
authors: Li
authors: Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military Medical Sciences, Beijing 100071, China.
authors: Xiaoqing
authors: X
authors: Liu
authors: Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military Medical Sciences, Beijing 100071, China.
authors: Fang
authors: F
authors: Gao
authors: Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military Medical Sciences, Beijing 100071, China.
authors: Xiaodan
authors: X
authors: Yin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D019046:Bone Marrow Neoplasms / Q000556:secondary*; D000077547:Crizotinib; D005260:Female; D050939:Gene Fusion; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases